ISRAEL CANCER RESEARCH FUND, INC.

FINANCIAL STATEMENTS

Years Ended December 31, 2012 and 2011

AND INDEPENDENT AUDITORS' REPORT

ISRAEL CANCER RESEARCH FUND, INC.

CONTENTS

December 31, 2012 and 2011

	Page
INDEPENDENT AUDITORS' REPORT	1-2
FINANCIAL STATEMENTS	
Statements of Financial Position	3
Statements of Activities	4
Statements of Functional Expenses	5-6
Statements of Cash Flows	7
Notes to Financial Statements	8-20

INDEPENDENT AUDITORS' REPORT



To the International Board of Trustees of Israel Cancer Research Fund, Inc.

We have audited the accompanying statements of financial position of Israel Cancer Research Fund, Inc. (a nonprofit organization), which comprise the financial position as of December 31, 2012 and 2011, and the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.





Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Israel Cancer Research Fund, Inc. as of December 31, 2012 and 2011, and the changes in its net assets and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

Reson Seymeur Shases Madin & Company KHP

CERTIFIED PUBLIC ACCOUNTANTS

New York, New York November 12, 2013

STATEMENTS OF FINANCIAL POSITION

December 31, 2012 and 2011

	2012	2011
Assets		
Current assets:		
Cash and cash equivalents:		
Bank deposits	\$ 2,298,637	\$ 1,513,322
Money market, unrestricted	3,593,491	2,516,510
Money market, temporarily restricted	1,144,813	1,386,304
Total cash and cash equivalents	7,036,941	5,416,136
Marketable securities	103,731	87,049
Unconditional promises to give, current portion, less allowances	1,551,336	1,356,492
of \$21,820 and \$0 for 2012 and 2011, respectively		
Prepaid expenses and other current assets	62,256	46,411
Total current assets	8,754,264	6,906,088
Equipment and improvements, net	53,869	55,998
Other assets:		
Money market, permanently restricted	36,514	678,836
U.S. treasury bonds, temporarily restricted	601,854	U=
U.S. treasury bonds, permanently restricted	1,426,329	752,498
Unconditional promises to give, net of current portion	624,428	1,158,207
Park naming rights	250,000	250,000
Deposits	19,342	19,342
Total assets	\$ 11,766,600	\$ 9,820,969
Liabilities and Net Assets		
Current liabilities:		
Accounts payable and accrued expenses	\$ 261,254	\$ 156,812
Research grants payable	1,120,000	666,250
Gift annuities payable, current portion	26,939	25,546
Total current liabilities	1,408,193	848,608
Other liabilities:		
Deferred rent payable	36,143	35,399
Gift annuities payable, net of current portion	56,615	83,554
Total liabilities	1,500,951	967,561
Commitments and contingency		
Net assets:		
Unrestricted	5,946,707	4,507,875
Temporarily restricted	2,890,105	2,916,696
Permanently restricted	1,428,837	1,428,837
Total net assets	10,265,649	8,853,408
Total liabilities and net assets	\$ 11,766,600	\$ 9,820,969

STATEMENTS OF ACTIVITIES

Years Ended December 31, 2012 and 2011

Net assets at end of year	Net assets at beginning of year	Increase (decrease) in net assets	Total expenses	Total sup	Supporting services: Management and general Fund-raising	Total pro	Expenses: Program services: Research Public information	Total rev	Revenues and public support: Contributions, legacies and be Investment income, net Special event income Less cost of direct benefit to c Donated services Net assets released from restr
of year	inning of year	se) in net assets	benses	Total supporting services	ices: and general	Total program services	eation	Total revenues and public support	evenues and public support: Contributions, legacies and bequests Investment income, net Special event income Less cost of direct benefit to donors Donated services Net assets released from restrictions
\$ 5,946,707	4,507,875	1,438,832	4,180,272	2,108,891	840,958 1,267,933	2,071,381	1,996,060 75,321	5,619,104	Unrestricted Net Assets \$ 2,511,227 2,916 1,632,954 (156,634) 681,909 946,732
\$ 2,890,105	2,916,696	(26,591)	1		1 1		1 . 3	(26,591)	Temporarily Restricted Net Assets \$ 865,385 54,756 (946,732)
\$ 1,428,837	1,428,837		ı	Ĩ.	1 1		ji r	i	Permanently Restricted Net Assets
\$ 10,265,649	8,853,408	1,412,241	4,180,272	2,108,891	840,958 1,267,933	2,071,381	1,996,060 75,321	5,592,513	Total \$ 3,376,612 \$ 57,672 1,632,954 (156,634) 681,909
\$ 4,507,875	3,811,067	696,808	3,691,013	2,100,017	1,067,771 1,032,246	1,590,996	1,522,801 68,195	4,387,821	Unrestricted Net Assets \$ 1,501,936 480 1,863,800 (274,381) 527,486 768,500
\$ 2,916,696	2,539,292	377,404			15 1	1	r 1	377,404	Temporarily Restricted Net Assets \$ 1,142,413 3,491 (768,500)
\$ 1,428,837	1,428,837	ī	1		30 I	1	1 1		Permanently Restricted Net Assets
\$ 8,853,408	7,779,196	1,074,212	3,691,013	2,100,017	1,067,771 1,032,246	1,590,996	1,522,801 68,195	4,765,225	Total \$ 2,644,349 \$ 3,971 1,863,800 (274,381) 527,486

STATEMENTS OF FUNCTIONAL EXPENSES

Year Ended December 31, 2012

Total expenses included in the expense section of the statement of activities	Less expenses included with revenues on the statement of activities	Total expenses	Depreciation Donated services	Total expenses before depreciation and donated services	Bad debts	Amortization of gift annuity	Website maintenance	Advertising and public relations	Conferences and meetings	Travel	Meals and entertainment	Equipment rental	Office and miscellaneous	Mailing, printing, and postage	Administration:	Outside services	Consulting and computer support	Accounting and legal	Professional fees:	Event facility rental	Telephone	Repairs and maintenance	Property and casualty insurance	Utilities	Rent	Occinancy.	Research grants: Grants awarded	Total compensation and related expenses	Employee benefits	Payroll taxes	Compensation and related expenses: Salaries and wages		
\$ 1,996,060		1,996,060	4,486 261,909	1,729,665		1	2,463	7,500	1	35,391	50 755 -	1,806	2,810	6,502						13,045	2,313	1,476		2,009	22,585		1,440,000	141,010	25,662		\$ 106,831	Research	F
\$ 75,321	1	75,321	1,854	73,467	ı	ı	1	7,500		801	7 473	746 218	555				1	ı		1	925	610		830	9,333		1	44,426	4,666	3,142	\$ 36,618	Public Information	Program Services
\$ 2,071,381	-1	2,071,381	6,340 261,909	1,803,132	1	1	2,463	15,000	1	36,192	58 178	2,332	3,365	6,502			1	1	,	13,045	3,238	2,086		2,839	31,918	, ,	1,440,000	185,436	30,328		\$ 143,449	Total	38
\$ 840,958	1	840,958	4,749 380,000	456,209	133	5,888	18,012	2,695	1,040	17,790	3 754	5,543	13,845	14,060		10,829	3,900	55,519		,	5,430	3,034	15,107	1,312	44,266		ī	222,153	29,223		\$ 178,626	Management and General	
\$ 1,267,933		1,267,933	9,269 40,000	1,218,664	48,137		8,456	30,925	3,902	45,498	50 573	25,658	23,334	201,128		73,039	70,000	12,106		24,424	5,292	3,051		4,151	46,662		1	517,548	63,860	33,460	\$ 420,228	Fund Raising	Supportin
S	(156,634)	156,634	1 1	156,634				1	ı	100,004	156 634	1		1		1				7	1	ı	1	Ę	ī		1	1	i	ı	⇔	Direct Benefit to Donors	Supporting Services
\$ 2,108,891	(156,634)	2,265,525	14,018 420,000	1,831,507	48,270	5,888	26,468	33,620	4,942	63.288	21,729	31,201	37,179	215,188		83,868	73,900	67,625		24,424	10,722	6,085	15,107	5,463	90,928			739,701	93,083		\$ 598,854	Total	
\$ 4,180,272	(156,634)	4,336,906	20,358 681,909	3,634,639	48,270	5,888	28,931	48,620	4,942	99,480	20,047	33,753	40,544	221,690		83,868	73,900	67,625	,	37,469	13,960	8,171	15,107	8,302	122,846	., ,	1,440,000	925,137	123,411		\$ 742,303	Total	

STATEMENTS OF FUNCTIONAL EXPENSES

Year Ended December 31, 2011

Total expenses before depreciation and donated services Depreciation Donated services Total expenses Less expenses included with revenues on the statement of activities Total expenses included in the expense section of the statement of activities	Administration: Mailing, printing and postage Office and miscellaneous Equipment rental Bank charges Meals and entertainment Travel Conferences and meetings Advertising and public relations Website maintenance Amortization of gift annuity Bad debts	Research grants: Grants awarded Occupancy: Rent Utilities Property and casualty insurance Repairs and maintenance Telephone Event facility rental Professional fees: Accounting and legal Consulting and computer support Outside services	Compensation and related expenses: Salaries and wages Payroll taxes Employee benefits Total compensation and related expenses
1,356,853 2,362 163,586 1,522,801 - \$ 1,522,801	5,913 2,927 1,842 76 34,495 21,292 7,500 565	1,095,000 21,800 2,010 102 1,449 2,646 31,347	Research \$ 95,407 7,848 24,634 127,889
67,506 689 - 68,195 - \$ 68,195	769 683 537 62 14,581 1,100 7,500	6,358 586 586 423 742 55	Public Information \$ 27,695 2,354 4,061 34,110
1,424,359 3,051 163,586 1,590,996	6,682 3,610 2,379 138 49,076 22,392 - 15,000 565	1,095,000 28,158 2,596 102 1,872 3,388 31,402	Total \$ 123,102 10,202 28,695 161,999
700,457 3,414 363,900 1,067,771 - \$ 1,067,771	15,168 33,223 6,767 11,705 2,772 21,984 1,596 7,369 187 7,207 59,215	44,565 1,592 15,401 1,207 7,091 48,625 22,020 60,708	Management and General \$ 272,075 21,094 38,886 332,055
1,027,326 4,920 - 1,032,246 - - - \$ 1,032,246	243,568 34,490 11,437 16,686 93,710 12,986 4,018 36,445 3,100 - 2,599	45,417 4,188 - 3,019 5,558 108,181 9,386 93,341 13,187	Supporting Services Direct Fund Benefit Raising Donor \$ 226,808 \$ 18,260 \$ 40,942 286,010
274,381 - - 274,381 (274,381) \$ -	274,381		Direct Benefit to Donors
2,002,164 8,334 363,900 2,374,398 (274,381) \$ 2,100,017	258,736 67,713 18,204 28,391 370,863 34,970 5,614 43,814 3,287 7,207 61,814	89,982 5,780 15,401 4,226 12,649 108,181 58,011 115,361 73,895	Total \$ 498,883 39,354 79,828 618,065
3,426,523 11,385 527,486 3,965,394 (274,381) \$ 3,691,013	265,418 71,323 20,583 28,529 419,939 57,362 5,614 58,814 3,852 7,207 61,814	1,095,000 118,140 8,376 15,503 6,098 16,037 139,583 58,011 115,361 73,895	Total \$ 621,985 49,556 108,523 780,064

STATEMENTS OF CASH FLOWS

Years Ended December 31, 2012 and 2011

	2012	2011
Cash flows from operating activities:		
Increase in net assets	\$ 1,412,241	\$ 1,074,212
Adjustments to reconcile increase in net assets to		
net cash provided by operating activities:		
Depreciation	20,358	11,385
Donated marketable securities	(260,279)	(217,680)
Deferred rent expense	744	2,857
Net realized and unrealized loss (gain) on investments	(755)	634
Changes in assets and liabilities:		
(Increase) decrease in:		
Unconditional promises to give	338,935	(804,932)
Prepaid expenses and other current assets	(15,846)	5,589
Increase (decrease) in:		
Accounts payable and accrued expenses	104,442	48,363
Research grants payable	453,750	193,750
Gift annuities payable	(25,546)	(24,228)
Net cash provided by operating activities	2,028,044	289,950
Cash flows from investing activities:		
Net purchases, sales and redemption of marketable securities	(389,011)	195,855
Purchase of equipment and improvements	(18,228)	(26,042)
Net cash (used in) provided by investing activities	(407,239)	169,813
Net increase in cash and cash equivalents	1,620,805	459,763
Cash and cash equivalents:		
Beginning of year	5,416,136	4,956,373
End of year	\$ 7,036,941	\$ 5,416,136

NOTES TO FINANCIAL STATEMENTS

December 31, 2012 and 2011

1. Summary of Significant Accounting Policies

Nature of Activities

Israel Cancer Research Fund, Inc. (the "Organization") was created as a nonprofit corporation in August 1975 to support cancer research in Israel. The Organization is exempt from federal income tax under Section 501(c)(3) of the Internal Revenue Code. The Organization is supported primarily through donor contributions, and maintains chapters and offices in New York, California, and Illinois. The Organization has affiliates in Toronto, Montreal and Jerusalem.

Basis of Accounting

The financial statements of the Organization have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and accordingly reflect all significant receivables, payables, and other liabilities.

Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires the use of management's estimates. The Organization uses estimates and assumptions in preparing financial statements. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates.

Cash and Cash Equivalents

For purposes of the statements of cash flows, the Organization considers all highly liquid investments with an initial maturity of three months or less to be cash equivalents.

Restricted Cash

The temporarily and permanently restricted cash represents funds received from donors restricted for research grants.

Marketable Securities and U.S. Treasury Bonds

The Organization carries investments in marketable securities and U.S. Treasury Bonds with readily determinable fair values and all investments in debt securities at their fair values in the statements of financial position. The Organization intends to hold investments in U.S. Treasury Bonds to maturity. Unrealized gains and losses are included in the change in net assets in the accompanying statements of activities. See Note 3 for a discussion of fair value measurements.

Investment Pools

The Organization maintains master investment accounts for its donor-restricted endowments. Income from securities in the master investment accounts are allocated monthly to the individual endowments based on the relationship of the market value of each endowment to the total market value of the master investment accounts, as adjusted for additions to or deductions from those accounts.

December 31, 2012 and 2011

Deferred Rent Payable

Deferred rent payable represents the excess of recognized rental expense over scheduled operating lease facility payments. This amount will be credited to future operations.

Net Assets Released From Restrictions

Support and other revenues restricted by donors are recorded initially as increases in temporarily restricted net assets in the reporting period in which the income and gains are recognized. When a restriction expires, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the statement of activities as net assets released from restrictions.

Equipment and Improvements and Depreciation

All acquisitions of equipment and improvements, above a certain amount are capitalized. Expenditures and betterments for repairs and maintenance that materially prolong the useful lives of assets are also capitalized. Equipment and improvements are carried at cost or, if donated, at the approximate fair value at the date of donation. Depreciation is computed primarily using the straight-line method. Leasehold improvements are depreciated over the lower of the asset's life or the term of the lease for office space. When equipment and improvements are retired, sold, or otherwise disposed of, the asset's carrying amount and related accumulated depreciation are removed from the accounts and any gain or loss is included in the Organization's activities.

Donated Assets

Donated marketable securities, including bonds and other noncash donations are recorded as contributions at their fair values at the date of donation.

Promises to Give

"Promises to Give" includes bequests that the Organization has been informed of, that it is a beneficiary from the estates of donors of blessed memory. In the case of bequests, the Organization records the best estimate of the anticipated bequest based on information available.

Unconditional promises to give are recognized as revenues (or gains) in the period received and as assets, decreases of liabilities, or expenses depending on the form of the benefits received. Conditional promises to give are recognized only when the conditions are met and the promises become unconditional (see Note 2).

Restricted and Unrestricted Revenue

Contributions received are recorded as increases in unrestricted, temporarily restricted, or permanently restricted net assets, depending on the existence and/or nature of any donor restrictions. Contributions without specific donor designation are recognized as unrestricted contributions.

The Organization has received gifts to establish endowments. The principal portion of permanent endowments is held in perpetuity and recorded as permanently restricted net assets. The principal portion of endowments that allow for the use of principal under

December 31, 2012 and 2011

certain conditions is recorded as temporarily restricted net assets. The income and net appreciation on endowments is recorded as unrestricted, temporarily restricted, or permanently restricted, as specified by the donors. Accrued interest on U.S. treasury bonds is included as permanently and temporarily restricted other assets until the cash is received.

Donated Services

The Organization generally pays for services requiring specific expertise. However, many individuals volunteer their time and perform a variety of tasks that assist the Organization with specific assistance programs, and various committee assignments. In accordance with GAAP, the Organization recognizes contributions of services only if the services received (a) create or enhance nonfinancial assets or (b) require specialized skills, are provided by individuals possessing those skills and would typically need to be purchased if not provided by donation. Donated professional services as part of a program, fundraising activity, or general and administrative expense are recorded as in-kind contributions in the accompanying financial statements at their fair value on date of use or receipt to the extent that such amounts can be reasonably estimated.

The value of such services was computed for the hourly rates of scientists that are on the Scientific Review Panel for the awarding of research grants (Note 9), lawyers of Latham & Watkins, LLP that performed pro-bono work for matters regarding unpaid promises to give, and Sentrix Health Communications for design services related to marketing materials and brochures. For the year ended December 31, 2012, the Organization received \$261,909 and

\$420,000, in program research services and in supporting management and general services, respectively. For the year ended December 31, 2011, the Organization received \$163,586 and \$363,900, in program research services and in supporting management and general services, respectively.

Expense Allocation

The costs of providing various programs and other activities have been summarized on a functional basis in the statements of activities and in the statements of functional expenses. Accordingly, certain costs have been allocated among the programs and supporting services benefits.

Income Tax Status

The Organization is exempt from federal income tax under Section 501(c)(3) of the Internal Revenue Code. In addition, the Organization qualifies for the charitable contribution deduction under Section 170(b)(1)(A) and has been classified as an organization other than a private foundation under Section 509(a)(1). The Organization's most recent determination letter from the Internal Revenue Service is dated February 1976. This status was confirmed by the Internal Revenue Service on December 7, 2006.

GAAP clarifies the accounting for uncertainty in income taxes recognized in a company's financial statements by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. The Organization has determined that it has no uncertain tax positions that require either recognition or disclosure in the financial statements.

December 31, 2012 and 2011

The Organization's information returns for 2009 through 2011 are subject to federal, state and local tax examinations by tax authorities.

2. Promises to Give

Unconditional Promises to Give

Ten of the Organization's "Unconditional Promises to Give" are multi-year pledges. Six of them are considered to be temporarily restricted. In accordance with GAAP, these pledges are recorded on the pledge date as contributions based on the present value of the gift on that date.

Unconditional promises to give at December 31, 2012 and 2011, are as follows:

	2012	2011
Bequests		
Unrestricted	\$ 1,121,000	\$ 650,501
Restricted for research grants	-	25,000
Pledges and other promises:		
Unrestricted	221,250	466,250
Restricted for research grants	1,001,500	1,702,000
Accounts receivable	100,486	165,909
	\$ 2,444,236	\$ 3,009,660
Receivable in less than one year	\$ 1,619,236	\$ 1,426,160
Receivable in one to five years	575,000	1,283,500
Receivable in more than five years	250,000	300,000
Total unconditional promises		
to give	2,444,236	3,009,660
Less discounts to net present value	(246,652)	(494,961)
Less allowance for uncollectible		
promises receivable	(21,820)	
Net unconditional promises to give at December 31, 2012		
and 2011	\$ 2,175,764	\$ 2,514,699

Unconditional promises to give due in more than one year are reflected at the net present value of estimated future cash flows using discount rates of 3.49% to 11.62% depending upon the date pledged.

In 2003 and 2004, respectively, a foundation entered into an unconditional professorship pledge agreement and a conditional fellowship pledge agreement with the Organization. In June 2012, an agreement was executed by the Organization and the foundation. Consideration was given to both pledge agreements made in the past, and the foundation agreed to satisfy all unpaid and future obligations by making an unconditional lump-sum payment to the Organization in the amount of \$550,000, which was received by the Organization in July 2012. The foundation also agreed to another unconditional pledge to fund a "New Professorship Grant" in the total sum of \$350,000, commencing in 2017. Under the new pledge, the foundation is to give \$50,000 per year, for a term of seven years, through 2023. Contribution income for the New Professorship Grant pledge is recognized in the year ended December 31, 2012.

Conditional Promises to Give

During the year ended December 31, 2011, the Organization received a \$25,000 contribution paid in full, contingent on the Organization establishing the Laureate Circle in New York, a premier group to recognize supporters. As of December 31, 2011, this amount is included in accounts payable and accrued expenses.

During the year ended December 31, 2012 the Organization established the Laureate Circle in New York and the amount was recognized as a contribution.

December 31, 2012 and 2011

3. <u>Investments</u>

The Organization accounts for its investments at fair value. GAAP has established a framework for measuring fair value that is based on a hierarchy which prioritizes the inputs to valuation techniques according to the degree of objectivity necessary. The fair value hierarchy of the inputs to valuation techniques used to measure fair value is divided into three broad levels of objectivity:

Level 1 Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Organization has the ability to access.

Level 2 Inputs to the valuation methodology include

- quoted prices for similar assets or liabilities in active markets;
- quoted prices for identical or similar assets or liabilities in inactive markets:
- inputs other than quoted prices that are observable for the asset or liability;
- inputs that are derived principally from or corroborated by observable market data by correlation or other means.

If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.

Level 3 Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Organization believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

The following tables present the Organization's fair value hierarchy for those assets measured at fair value on a recurring basis as of December 31, 2012 and 2011:

		Decembe	r 31, 2012	
	Level 1	Level 2	Level 3	Total
Equity securities: Domestic equities Fixed income securities:	\$ 15,345	\$ -	\$ -	\$ 15,345
U.S. government bonds	2,028,183		-	2,028,183
Israel government bonds	88,386			88,386
	\$2,131,914	\$ -	<u>\$ -</u>	\$2,131,914
		Decembe	r 31, 2011	
	Level 1	Level 2	Level 3	Total
Equity securities: Domestic equities Fixed income securities:	\$ 11,303	\$ -	\$:=	\$ 11,303
U.S. government bonds	752,498		- 1	752,498
Israel government bonds	75,746			75,746
	\$ 839,547	<u>s -</u>	\$ -	\$ 839,547

December 31, 2012 and 2011

Level 1 Gains and Losses

Investment return for the years ended December 31, 2012 and 2011 and its classification in the statements of activities is summarized as follows:

	2012	2011
Investment income: Interest and dividends	\$ 55,510	\$ 1,086
Net realized and unrealized gains/(losses) on investments:		
Realized and unrealized gains/(losses)	755	(634)
	\$ 56,265	\$ 452

4. Equipment and Improvements

As of December 31, 2012 and 2011, equipment and improvements consist of the following:

		2011
Leasehold improvements	\$ 4,883	\$ 4,883
Equipment	109,576	94,885
Furniture and fixtures	22,320	22,482
	136,779	122,250
Accumulated depreciation	82,910	66,252
	\$ 53,869	\$ 55,998

Depreciation expense amounted to \$20,358 and \$11,385 for the years ended December 31, 2012 and 2011, respectively.

5. Research Grants Payable

Grants Authorized But Unpaid

Grants of \$1,120,000 and \$666,250, authorized but unpaid as of December 31, 2012 and 2011, respectively, are reported as liabilities.

Conditional Grants

Conditional grant obligations, which are not included in the accompanying statements of financial position, are dependent upon approval by the Scientific Review Panel and the Organization's ability to pay. Awarded obligations by grant year, which generally runs from September through August, as of December 31, 2012, are as follows:

Grant Year	Expected Awards
2013-14	\$ 965,000
2014-15	325,000
2015-16	150,000
2016-17	100,000
2017-18	50,000
Thereafter	50,000
	\$ 1,640,000

6. Split-Interest Agreements

Charitable Gift Annuities

A charitable gift annuity is an arrangement between a donor and the Organization in which the donor contributes assets to the Organization in exchange for a promise by the Organization to pay a fixed amount for a specified period of time to the donor or to individuals or organizations designated by the donor. Assets received by the Organization under such agreements are recorded at fair value on the date of execution. In the case of annuities to be paid over the remaining lives of the beneficiaries, an annuity liability is recorded based on life expectancy tables published by the Internal Revenue Service for retirement distributions, which the Organization believes to be a reasonable actuarial estimate for this type of split-interest agree-

December 31, 2012 and 2011

ment. The difference between the fair value of the assets donated and the annuity liability is recorded as unrestricted contribution revenue, unless donor-imposed restrictions or state law require other recognition. Amortization over the term of an annuity is provided for using a discount rate equal to the yield, at the date of execution, indicated by Merrill Lynch's index for "AAA"-rated corporate bonds with maturities in the range of the annuity term.

The annual change in value of such splitinterest agreements of \$5,888 and \$7,207 in 2012 and 2011, respectively, is recognized in the accompanying statements of activities.

7. Temporarily Restricted Net Assets

Temporarily restricted net assets of \$2,890,105 and \$2,916,696 as of December 31, 2012 and 2011, respectively, are available for subsequent years' grant awards and other program activities. These amounts include \$2,113,957 and \$1,636,237 as of December 31, 2012 and 2011, respectively, of endowments and investment returns on permanent endowments and \$776,148 and \$1,280,459 as of December 31, 2012 and 2011, respectively, arising from promises to give and other assets.

8. Endowment Funds

Permanently restricted net assets as of December 31, 2012 and 2011 consist of endowment funds to support cancer research in Israel. Contributions to the endowment funds are subject to donor restrictions that stipulate the original principal of the gift is to be held and invested by the Organization indefinitely and income from the funds is to

be expended for cancer research in Israel. The historic dollar value of those contributions must be maintained inviolate. Income from the fund is classified as temporarily restricted net assets until the purpose of the restriction is satisfied. When the purpose of the restriction is met, the net assets are reclassified to unrestricted net assets.

All donor-restricted endowment funds are invested in fixed income instruments pursuant to the Organization's investment and spending objectives of subjecting the funds to low investment risk and providing current income. The Organization generally expends the endowment funds' investment income for the donor-designated purpose when sufficient funds are available.

The composition of endowment net assets for these funds and the changes in endowment net assets as of December 31, 2012 and 2011 are as follows:

	Temporarily Restricted	Permanently Restricted	Total
Endowment net assets,			
January 1, 2011	\$ 1,579,027	\$ 1,428,837	\$ 3,007,864
Contributions	542,297		542,297
Investment income	8,413	54	8,413
Program expenditures	(493,500)		(493,500)
Endowment net assets,			
December 31, 2011	1,636,237	1,428,837	3,065,074
Contributions	985,906	- 1	985,906
Investment income	54,755		54,755
Program expenditures	(562,941)		(562,941)
Endowment net assets,			
December 31, 2012	\$ 2,113,957	\$ 1,428,837	\$ 3,542,794

December 31, 2012 and 2011

9. Description of Program and Supporting Services

The following program and supporting services are included in the accompanying financial statements:

Research

The Organization annually awards grants to research scientists in Israel. Scientists send proposals to the Organization. These proposals are then graded and scored by the Organization's Scientific Review Panels. The proposals are finally reviewed by the Organization's International Scientific Council, which presents recommendations to the Organization's International Board of Trustees, through its Chairman, for approval.

Grants are made by the Organization based on the evaluations of the International Scientific Council and the amount of funding available to support the grant proposals. The Organization has always had more proposals worthy of funding than funds available.

The Organization awards seven types of grants, as follows:

- (a) Distinguished Chairs, which are awarded to full-time senior faculty or persons in equivalent positions, and who have been honored with top international awards, such as a Nobel Prize, for their outstanding contributions to cancer research. The current grant for a Distinguished Chair is \$200,000 per year for five years, or a total of \$1,000,000.
- (b) Professorships, which are awarded to full-time senior faculty or persons in

- equivalent positions who have made outstanding contributions to cancer research. The current grant for a Professorship is \$50,000 per year for seven years, or a total of \$350,000.
- (c) Clinical Research Career Development Awards, which are awarded to promising young medical or pediatric oncologists to afford them time to conduct clinical research projects and to obtain additional training to become leaders in clinical research programs. The current grant for a Clinical Research Career Development Award is \$45,000 per year for three years, or a total of \$135,000.
- (d) Research Career Development Awards, which are awarded to promising cancer researchers who have advanced beyond the postdoctoral level and are well on their way to becoming outstanding independent investigators. The current grant for a Research Career Development Award is \$35,000 per year for three years, or a total of \$105,000.
- (e) Acceleration Grants, which are intended to speed up our efforts to fully understand the biology behind cancer. Recipients are required to propose highly-innovative approaches that have the promise of pioneering new ways of thinking about cancer biology and therapeutics. The current grant for an Acceleration Grant is \$50,000 per year for two years, or a total of \$100,000.
- (f) Project Grants, which are awarded to support the research of established investigators working on specific projects. The current grant for a Project

December 31, 2012 and 2011

Grant is \$30,000 per year for two years, or a total of \$60,000.

(f) Postdoctoral Fellowships, which are awarded to new M.D.s and Ph.D.s who will apprentice in the laboratories of senior investigators. The current grant for a Postdoctoral Fellowship is \$25,000 per year for two years, or a total of \$50,000.

An additional 10% for indirect cost recovery is requested from all cancer research grant sponsors.

During 2012, the Organization funded scientists at eight research institutions in Israel. The Organization has arranged that all funds granted are provided to the scientists for research, with no overhead charge paid to the institutions.

Scientists funded by the Organization have done outstanding work, conducting basic research which has led to effective prescription medications. Two scientists funded by the Organization were awarded the Nobel Prize in Chemistry in 2004.

All grants awarded by the Organization are contingent upon the awardees conducting the specific research contemplated in their proposals and upon the Organization having sufficient means to make payments to the awardees.

Although it is frequently the intention of the Organization to award grants that will extend over multiple years, each multi-year grant is subject to an annual review and re-approval by the International Scientific Council. Accordingly, only the amount of grants awarded or

approved in the current year is reported as an expense in the accompanying financial statements.

Public Information

The Organization publishes information that encourages an understanding of all aspects of cancer, its treatments and the research that is ongoing in Israel and across the globe to stem the spread and devastation of the disease.

Management and General

Includes the functions necessary to maintain an equitable employment program; ensure an adequate working environment; provide coordination and articulation of the Organization's program strategy; secure proper administrative functioning of the International Board of Trustees; maintain competent legal services for the program administration of the Organization; and manage the financial and budgetary responsibilities of the Organization.

Management and general expenses accounted for 20.1% and 28.9% of total expenses for the years ended December 31, 2012 and 2011, respectively.

Fund-Raising

Provides the structure necessary to encourage and secure private financial support from individuals, foundations, and corporations. Fund-raising activities represented 30.3% and 28.0% of the Organization's total expenses for the years ended December 31, 2012 and 2011, respectively.

December 31, 2012 and 2011

10. Advertising

The Organization uses advertising and public relations services to promote its programs among the audiences it serves. The costs of advertising are expensed as incurred. During 2012 and 2011, advertising and public relations costs totaled \$48,620, or 1.2%, and \$58,814, or 1.6%, respectively, of total expenses.

11. Employee Benefit Plans

Tax-Deferred Annuity Plan

The Organization maintains a tax-deferred annuity plan ("Plan") qualified under Section 403(b) of the Internal Revenue Code. When employees are hired they are eligible to participate in the Plan. The Plan covers all eligible employees of the Organization who have elected to participate in the Plan. The Organization contributes 2% of gross salaries for qualified employees to the Plan. Employees may make contributions to the Plan up to the maximum amount allowed by the Internal Revenue Code if they wish. In 2012 and 2011, plan expense, representing the Organization's contributions to the Plan, was approximately \$12,000 and \$10,000, respectively.

12. Financial Instruments

Concentrations of Credit Risk Due to Temporary Cash Investments and Promises to Give Receivable

Financial instruments that potentially subject the Organization to credit risk consist principally of temporary cash investments and receivables from promises to give. The Organization places its temporary cash investments in multiple accounts with a brokerage firm; thereby limiting the amount of credit exposure to any one account. The account at the brokerage firm contains cash, money market funds and other securities. Individual account balances are insured up to \$500,000, with a limit of \$100,000 for cash and \$400,000 for securities, by the Securities Investor Protection Corporation ("SIPC"). As of December 31, 2012 and 2011, the Organization had approximately \$4,810,000 and \$3,360,000, respectively, in excess of SIPC insured limits.

Concentrations of credit risk with respect to promises receivable depend on the number of contributors comprising the Organization's contributor base and their dispersion across different industries and geographic areas. As of December 31, 2012 and 2011, 77% and 52%, respectively, of the Organization's receivables from promises to give were from three donors.

Concentrations of Risk of Loss Arising From Cash Deposits in Excess of Insured Limits

The Organization maintains cash balances and U.S. treasury bonds at several financial institutions. Accounts at each institution are insured by the Federal Deposit Insurance Corporation ("FDIC") up to the FDIC insured limit of \$250,000 for cash. As of December 31, 2012 and 2011, the Organization's uninsured cash balances totaled approximately \$1,310,000 and \$640,000, respectively.

Fair Values of Financial Instruments

The Organization has a number of financial instruments, consisting primarily of U.S.

December 31, 2012 and 2011

Treasury bonds, other government bonds, money market accounts, certificates of deposit and high-grade corporate bonds. The Organization has determined that the fair value of all financial instruments as of December 31, 2012 and 2011, does not differ materially from the aggregate carrying values of its financial instruments recorded in the accompanying statements of financial position (Note 3).

13. Commitments

Lease Commitments

The Organization has noncancelable operating leases for offices in New York and California and parking spaces in California that expire at various dates through February, 2017. Rental expenses for those leases were \$118,735 and \$116,389 for the years ended December 31, 2012 and 2011, respectively.

Future minimum lease payments under operating leases that have remaining terms in excess of one year as of December 31, 2012, including the leases referred to above, are:

Years Ending December 31,	Minimum
December 51,	Payments
2013	\$ 125,481
2014	133,314
2015	113,969
2016	108,696
2017	23,488
	\$ 504,948

14. Related Entities

The Organization has three affiliates that serve as local chapters of the Organization in

Canada and Israel. The Organization has no ownership or voting interests in these local chapters. However, agreements between the local chapters and the Organization give the Organization involvement in the awarding of research grants by the local chapters through its International Board of Trustees and Scientific Review Panels. The Organization awarded \$1,315,000 and \$1,405,000 of grants on behalf of its Canadian and Israeli affiliates in 2012 and 2011, respectively.

15. Intangible Assets

In March 2004, the Organization invested \$250,000 in the development of a park in Israel. In return, the Organization received naming rights to the park and the right to construct a "Donor Wall" in the park. It is the Organization's plan to offer organizations or individuals, on a fee basis, the right to name the park and its physical assets (benches, gazebos, etc.) and to inscribe the names of large donors on the Donor Wall. An initial donation of \$219,107 was made by an estate to offset the costs of the park in return for a marker stone naming the donor. Consequently, Organization has capitalized the development cost of \$250,000 in the accompanying statements of financial position. The Organization has implemented a capital plan to attract these contributions by expanding its marketing material and outreach. At such time as expected future cash flows can be reasonably estimated, an amortization life will be assigned to the intangible asset in order to properly match the expense associated with the acquisition of the asset to the periods of benefit.

December 31, 2012 and 2011

16. Costs of Joint Activities

Direct Mail

The Organization may achieve some of its programmatic and management and general goals in direct mail campaigns that include requests for contributions. If certain criteria related to the purpose, audience and content of the mailings are met, joint costs that are not directly attributable to either the program or management and general components, or the fund-raising component, of the mailing are allocated based on the relative importance of each function to the campaign. For the years ended December 31, 2012 and 2011, all costs related to direct mail campaigns were attributable to fund-raising.

Special Events

The Organization conducts special events during the course of the year, such as an annual dinner, educational seminars, and other events intended to further the mission of the Organization and to solicit funds for the continued support of that mission. If certain criteria related to the purpose, audience and

content of the event are met, costs incurred jointly to support the program or management and general functions, and the fund-raising functions of the event, are allocated to the appropriate functional categories in the statements of functional expenses. If the criteria related to the purpose, audience and content of the event are not met, all costs of the event are considered fund-raising expenses. In all cases, the cost of goods or services provided in an exchange transaction that is part of the joint activity, such as costs of direct donor benefits of a special event (e.g., a meal) is not reported as fundraising costs but rather as a net reduction of special event income in the statements of activities. For the years ended December 31, 2012 and 2011, all special event expenses, except for the cost of direct benefit to donors, were attributable to fund-raising.

17. Subsequent Events

The Organization has evaluated subsequent events through November 12, 2013, the date the financial statements were available to be issued. The Company had no material subsequent events requiring disclosure.